Neonatal Immunoreactive Trypsin kit（IRT）

96 servings/kit & 960 servings/kit 

Overview

Immunoreactive Trypsin (IRT) is a screening method that detects the risk of cystic fibrosis (Cystic Fibrosis) in newborns. Cystic fibrosis is a common genetic disease that primarily affects the respiratory, pancreatic, and digestive systems. In people with cystic fibrosis, damaged protein channels cause mucus to accumulate in various parts of the body, affecting physiological functions.

The purpose of IRT screening for newborns is to detect the risk of cystic fibrosis early and intervene as early as possible to improve the patient's quality of life and prevent potential complications. By performing IRT screening in the early stages of neonatal life, further diagnostic confirmation and the development of a treatment plan can be carried out in a timely manner, with the goal of improving patient survival and reducing the severity of the disease.

Globally, early screening and diagnosis of genetic diseases such as cystic fibrosis play an important role in reducing the negative impact of the disease, avoiding the continuation of family genetic risks and improving the quality of life of patients. Therefore, IRT screening of newborns can help early detection and intervention of such genetic diseases, which will have an important global impact on reducing the severity of patients' conditions and improving their quality of life.

Neonatal Immunoreactive Trypsin kit

Neonatal Immunoreactive Trypsin kit is used as an aid for screening the neonatal cystic fibrosis (CF). The product is intended for the quantitative determination of immunoreactive trypsin (IRT) in neonatal blood specimens dried on filter paper.

Specifications

Other Specifications